IQVIA Holdings Inc. (NYSE:IQV) Stake Raised by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 6.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,001 shares of the medical research company’s stock after acquiring an additional 3,236 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in IQVIA were worth $9,826,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. LRI Investments LLC lifted its stake in IQVIA by 1.0% in the 4th quarter. LRI Investments LLC now owns 24,072 shares of the medical research company’s stock worth $4,730,000 after acquiring an additional 249 shares in the last quarter. Invenomic Capital Management LP purchased a new stake in IQVIA in the 4th quarter worth about $10,444,000. Investment Management Corp of Ontario lifted its stake in IQVIA by 102.4% in the 4th quarter. Investment Management Corp of Ontario now owns 12,242 shares of the medical research company’s stock worth $2,406,000 after acquiring an additional 6,193 shares in the last quarter. Jefferies Financial Group Inc. lifted its stake in IQVIA by 147.8% in the 4th quarter. Jefferies Financial Group Inc. now owns 50,476 shares of the medical research company’s stock worth $9,919,000 after acquiring an additional 30,108 shares in the last quarter. Finally, Humankind Investments LLC lifted its stake in IQVIA by 30.1% in the 4th quarter. Humankind Investments LLC now owns 4,190 shares of the medical research company’s stock worth $823,000 after acquiring an additional 970 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Up 1.6%

IQV opened at $142.66 on Friday. The business has a 50 day moving average price of $159.83 and a 200 day moving average price of $186.07. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market cap of $24.68 billion, a P/E ratio of 19.02, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the previous year, the business posted $2.54 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on IQV. Robert W. Baird cut their price target on IQVIA from $195.00 to $161.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Hsbc Global Res lowered IQVIA from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. UBS Group reduced their price target on IQVIA from $255.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Finally, Morgan Stanley lifted their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $230.76.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.